• Username (E-mail)
  • Password
Dow 19,827 0.5%  EStoxx50 3,299 0.3%  Nikkei 19,138 0.3%  EUR 1.0702 0.4% 
Nasdaq 5,555 0.3%  FTSE100 7,198 -0.1%  Yen 114.6250 0.0%  Oil 55.5 2.4% 
S&P500 2,271 0.3%  DAX 11,630 0.3%  GBP 1.2380 0.4%  Gold 1,214 -0.5% 

Biogen share [Symbol: BIIB / ISIN: US09062X1037]

Realtimequote Biogen Inc in USD

Exchange Market
280.66
Last
70,471
Volume
Time 03:59 PM
01/20/2017 03:59:59 PM UTC-0500
activate push

Stock Price Biogen Inc in USD

Activate push
280.66 USD 0.31 USD 0.11 %
Trade Time 8:10 PM Trade Date 1/20/2017
Daily High 282.51 Open 282.07
Daily Low 279.41 Prev. Close 280.66
52-week High 333.24 Volume (Qty.) 657,854
52-week Low 223.03 Market Cap (USD) 60.92 B
52-week Perf.
Exchange

Analyst Opinions for Biogen Inc

More Analyst Opinions
  • All
  • Buy
  • Hold
  • Sell
12/17/12
Biogen Goldman Sachs Group Inc.
12/11/12
Biogen Credit Suisse Group
10/18/12
Biogen Jefferies & Company Inc.
10/12/12
Biogen UBS AG
09/28/12
Biogen Jefferies & Company Inc.

Moody's Rating for Biogen Inc

Investment Grade (High Grade)
Investment Grade (Medium Grade)
Speculative Grade
Rating Baa1
Rating Update AFF
Date of Rating 9/10/2015
Rating Office USA

Profile Biogen Inc

Company Profile
Biogen, Inc. is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for hemophilia B and ELOCTATE for hemophilia A. The company also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is approved for the treatment of chronic lymphocytic leukemia. Biogen was founded by Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
pagehit

Add or Edit Instrument

Biogen Chart - 1 Year - NAS
  • Intraday
  • 1w
  • 3 Mo.
  • 1y
  • 3y
  • 5y
  • Max
  • Exchange: NAS
  • Chart Options

Estimates for Biogen

2015 2016e 2017e
Dividend - - -
Dividend Yield in % - - -
P/E Ratio 18.00 14.24 13.67
EPS 17.01 20.17 21.01

Biogen Key Figures

Market Cap (USD) 60.92 B
Free Float in % 99.84
Number of Shares (Mio.) 217.57
Cash Flow per Share 15.25
Book Value per Share 42.66
60-Days Volatility 34.46
P/B Ratio 7.18

Base Data Biogen

Symbol BIIB
ISIN US09062X1037
Indices NASDAQ 100, S&P 100, NASDAQ Comp., S&P 500, BX Swiss - USA

About the Company Biogen

Country USA

Biogen Historical Prices

01/19/2017
01/19/2017 06:00:00 PM UTC-0500
280.66 657,854
01/18/2017
01/18/2017 06:00:00 PM UTC-0500
280.35 495,665
01/17/2017
01/17/2017 06:00:00 PM UTC-0500
283.61 383,326
01/16/2017
01/16/2017 06:00:00 PM UTC-0500
283.01 560,351
01/12/2017
01/12/2017 06:00:00 PM UTC-0500
284.75 567,274

Biogen Peer Group

Agennix 0.08
0.0%
Amgen 154.67
0.6%
BB BIOTECH 53.95
0.7%
Bayer 102.20
0.2%
Biogen 280.66
0.1%
Biotest 17.42
1.3%
EVOTEC 7.43
-1.9%
Gilead Sciences 71.01
-0.8%
KWS SAAT 288.65
2.1%
MorphoSys 48.35
-0.8%
QIAGEN 25.95
-1.7%
QIAGEN 25.95
-1.7%
Sartorius vz 69.26
0.8%
UCB 63.27
-0.4%

Similar shares with higher 1-year perf.